Among patients, lymphedema is one of the most feared consequences of cancer treatment and can be a lifelong, chronic condition if left untreated. Of the nearly 17 million cancer survivors in the U.S., roughly one in three treated for breast cancer, melanoma and pelvic cancers will develop chronic lymphedema1,2.
Watch New Clinical Evidence!
Recent clinical studies have shown advancements in how a surveillance model-of-care along with L-Dex® can aid in the detection of cancer-related lymphedema and PREVENT it from becoming a chronic condition for the patient.
A recent meta-analysis of 67,000 patients confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex technology, combined with early intervention, cuts the relative rate of chronic cancer-related lymphedema by 81% when compared to circumference monitoring3.
Bioimpedance spectroscopy (BIS) is the only reliable, non-invasive tool that can accurately detect accumulation of fluid related to subclinical lymphedema, in less than 30 seconds.
To avoid chronic, lifelong lymphedema, patients must be monitored early and periodically – before the condition becomes irreversible. Learn more about how implementing the Lymphedema Prevention Program can help cancer patients avoid this chronic condition4.
For Lymphedema Awareness Month, join millions of patients and healthcare professionals in recognizing and advocating for the improvement of patient care and access for those at-risk or suffering from lymphedema. Here are 5-ways to get involved:
Lymphedema is one of the most feared consequences of cancer treatment. Ensure the best possible outcome for patient survivorship by discussing the risk factors, treatment, and prevention with your patients. Check out our patient education support materials available for download.
Advances in surgical and radiation techniques are helping healthcare professionals proactively address lymphedema onset. Learn more on what measures are being taken to help patients avoid chronic lymphedema at the time of treatment and beyond.
Recent data demonstrates that breast cancer patients monitored using bioimpedance spectroscopy reduced the incidence of chronic cancer-related lymphedema by 81% versus circumference monitoring3.
For the latest information, download our billing and coding guide.
Early detection and treatment are critical to preventing cancer-related lymphedema4. Leading cancer institutions across the nation are seeing consistent reduction in lymphedema progression, trial after trial. Explore the study here and contact us to learn more about successful implementation of a Lymphedema Prevention Program.